Monthly Archives: July 2022

STEMTECH CORPORATION Partners with VERB in Launching Interactive Video and Livestreaming Sales Enablement Apps to Strengthen Direct Sales Channel -…

Posted: July 27, 2022 at 3:12 am

Florida-based nutraceutical company looks to increase customer engagement and drive salesconversion rates by deploying VERBs powerful interactive video-based sales tools

MIRAMAR, FL, and NEWPORT BEACH, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Stemtech Corporation (Stemtech) (OTCQB: STEK), an innovative nutraceutical company and a pioneer in the field of stem cell nutrition, today announced that Stemtech has adopted a suite of sales enablement software solutions, developed by Verb Technology Company, Inc. (Nasdaq: VERB), including verbCRM, VERBs white-labelled interactive video-based customer relationship management application, and verbLIVE, VERBs interactive livestream eCommerce and shoppable video and webinar application, for use in direct selling and customer and prospect communications by its network of Independent Business Partners (IBPs).

Stemtech specializes in creating products and formulas that are patent protected in the U.S. and international markets. Its patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. Its products are all-natural, plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). Stemtech has a history of innovation, was the first to market in the category of stem cell nutrition and was recognized four separate times by Inc. 5000 Fastest-Growing Companies list. Stemtechs primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income-earning potential to IBPs.

VERB is the leader in interactive video-based sales enablement applications, including interactive livestream eCommerce and shoppable video, webinar, CRM, and marketing applications for enterprises and entrepreneurs., verbCRM, VERBs interactive video-based customer relationship and content management system, will be used as a selling tool by Stemtechs IBPs in marketing its products, acquiring new customers, and strengthening existing customer relationships. The platform allows users to easily manage, share directly with customers and prospects and through social media, and track interactive content, such as product literature and media, demo videos, and personalized videos. It provides interaction analytics so IBPs can determine which content is resonating with their prospects and assess overall customer engagement and campaign effectiveness. This enables IBPs to focus their time and energy more effectively on high-probability sales prospects who have shown interest, thereby increasing their sales conversion rates. Stemtechs verbCRM implementation also includes VERBs Business Tiles feature, which integrates verbCRM directly into Stemtechs back-office systems, allowing IBPs access to key reports and metrics relevant to improving their business-building efforts natively on the verbCRM app. verbLIVE, VERBs powerful interactive livestream ecommerce application, will be used by IBPs to engage directly with customers and prospects during live video sessions that allow viewers to quickly buy, receive additional product information, set up appointments, and access other customizable interactive features through clickable in-video buttons.

We are dedicated to supporting and empowering Stemtechs expansive network of Independent Business Partners by equipping them with the most current and best-in-class digital technology sales tools available, said John W. Meyer, President and COO of Stemtech. With VERBs sales enablement applications, our IBPs will be able to capitalize on our social media assets and content and more effectively engage with customers and prospects via livestream video to bolster our customer acquisition efforts and increase sales conversion rates.

Stemtechs Vice President of Global Performance, Sandra Kazickaite, says our select Field IBPs who have been beta testing the new mobile app Stemtech Advance Office, powered by VERB, has been very successful and we are all most excited to launch shortly.

We are thrilled to include Stemtech among the forward-thinking companies that have embraced VERBs interactive video and livestreaming technology to grow sales, said Rory J. Cutaia, CEO of VERB. VERB has developed a suite of easy-to-use products that create a friction-free, fun, social, and video-based sales experience to enhance customer engagement, while providing real-time viewer engagement analytics for more effective follow-ups that drive sales conversion rates. We are proud to be Stemtechs technology partner to help empower its Independent Business Partners with industry-leading sales enablement tools.

About Stemtech Corporation

Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent protected in the U.S. and in select international markets. The Companys patented formulas help the release, circulation and migration of the bodys adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3, Stemflo MigraStem, OraStem (Oral Health Care), and D-Fuze (EMF blocker). Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit http://www.stemtech.com.

About VERB

Verb Technology Company, Inc. (Nasdaq: VERB), the market leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The Companys Software-as-a-Service, or SaaS, platform is based on its proprietary interactive video technology, and is comprised of a suite of sales enablement business software products offered on a subscription basis. Its software applications are used by hundreds of thousands of people in over 60 countries and in more than 48 languages. VERBs clients include large sales-based enterprises as well as small business sales teams, including the sales and marketing departments of professional sports teams. MARKET is VERBs multi-vendor, multi-presenter, livestream social shopping platform at the forefront of the convergence of ecommerce and entertainment. With approximately 180 employees, the Company is headquartered in Lehi, Utah, and it also maintains offices in Newport Beach, California.

For more information, please visit: http://www.verb.tech.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed onMay 16th, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

Follow VERB here:VERB on Facebook:https://www.facebook.com/VerbTechCo/VERB on Twitter:https://twitter.com/VerbTech_CoVERB on LinkedIn:https://www.linkedin.com/company/verb-tech/VERB on YouTube: https://www.youtube.com/channel/UC0eCb_fwQlwEG3ywHDJ4_KQDownload verbMAIL here: verbMAIL on Microsoft AppSource Store

See more here:
STEMTECH CORPORATION Partners with VERB in Launching Interactive Video and Livestreaming Sales Enablement Apps to Strengthen Direct Sales Channel -...

Posted in Utah Stem Cells | Comments Off

Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell…

Posted: July 27, 2022 at 3:12 am

The new report titled Tendon Stem Cell Therapy Market offer by Key Players, Types, Applications, Countries, Market Size, Forecast to 2030offered by Market Research, Inc. includes a comprehensive analysis of the market size, geographical landscape along with the revenue estimation of the industry. In addition, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Tendon Stem Cell Therapy Market.

Tendon disorders are frequently found in nonprofessional or proficient individuals. These disorders are characterized by swelling, pain, torment, and practical limitation of the affected ligament. Non-steroidal drugs, shockwave treatment, corticosteroids, platelet-rich plasma, and medical procedure are used for the treatment of tendon disorders. Recently Tendon Stem Cell Therapy is used for the treatment of tendon disorders.

Click the link to get a Sample Copy of the Report: https://www.marketresearchinc.com/request-sample.php?id=115638

This market study covers and analyzes the potential of the global Tendon Stem Cell Therapy industry, providing geometric information about market dynamics, growth factors, major challenges, PEST analysis and market entry strategy analysis, opportunities and forecasts. One of the major highpoints of the report is to provide companies in the industry with a strategic analysis of the impact of COVID-19 on Tendon Stem Cell Therapy market.

Tendon Stem Cell Therapy Market: Competition Landscape

The Tendon Stem Cell Therapy market report includes information on the product presentations, sustainability and prospects of leading player including: Cellualar Dynamics, Cellectis, International Stem cell Corporation, and Mesoblast Ltd

Tendon Stem Cell Therapy Market: Segmentation

By Type:

By Therapy Type:

By Application:

Tendon Stem Cell Therapy Market: Regional Analysis

All the regional segmentation has been studied based on recent and future trends and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Tendon Stem Cell Therapy market report are North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and Latin America.

Years Considered for the Tendon Stem Cell Therapy Market Size:

Key Benefits of the report:

Ask for Discount: https://www.marketresearchinc.com/ask-for-discount.php?id=115638

Major Points Covered in TOC:

Market Summary: It incorporates six sections, research scope, major players covered, market segments by type, Tendon Stem Cell Therapy market segments by application, study goals and years considered.

Market Landscape: Here, the global Tendon Stem Cell Therapy Market is dissected, by value, income, volume, market rate, and most recent patterns. The development and consolidation of the overall industry and top organizations is provided through graphs and piece of the pie for organizations.

Profiles of Companies: Here, driving players of the worldwide Tendon Stem Cell Therapy market are considered depending on sales across regions, key innovations, net income, cost, and other factors.

Market Status and Outlook by Region: In this segment, the report examines the net deals, income, creation and portion of the overall industry, CAGR and market size by locale. The global Tendon Stem Cell Therapy Market is profoundly examined based on areas and nations like North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Segment Analysis: Accurate and reliable foretell about the market share of the essential sections of the Tendon Stem Cell Therapy market is provided

Market Forecasts: In this section, accurate and validated values of the total market size in terms of value and volume are provided by the research analysts. Also, the report includes production, consumption, sales, and other forecasts for the global Tendon Stem Cell Therapy Market.

Market Trends: Deep dive analysis of the markets recent and future trends are provided in this section.

Enquiry before buying this premium Report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=115638

Market Research Inc

Author: Kevin

US Address: 51 Yerba Buena Lane, Ground Suite,

Inner Sunset San Francisco, CA 94103, USA

Call Us: +1 (628) 225-1818

Write Us: [emailprotected]

Posted in Stem Cell Research | Comments Off

Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. – PR Newswire

Posted: July 27, 2022 at 3:12 am

SAN FRANCISCO, July 21, 2022 /PRNewswire/ -- The global cell culture media market size is expected to reach USD 10.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2022 to 2030. Expansion of biosimilars and biologics, growth in stem cell research, and emerging bio manufacturing technologies for cell-based vaccines are the major factors which are likely to drive the market. For instance, in October 2021, the Australian Government funded the Australian-led stem cell research through USD 25 million in grants.

Key Industry Insights & Findings from the report:

Read 150-page market research report, "Cell Culture Media Market Size, Share & Trends Analysis Report By Product (Serum-free Media, Classical Media), By Type (Liquid Media, Semi-solid And Solid Media), By Application, By End-user, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Cell Culture Media Market Growth & Trends

The expansion of clear, regulatory approval paths for biosimilars in emerging markets is generating great opportunities for biosimilar monoclonal antibodies. The availability of an approval pathway in the U.S., has led to new opportunities for bio manufacturers to enter major markets around the globe. Biosimilar versions of monoclonal antibodies have the probability to offer cost reductions of 25-30%, and many emerging market countries are vigorously developing pathways for approvals and are swiftly catching up. As this industry is expanding the key biopharmaceutical players are adopting robust culturing technologies to meet the increasing demand; thereby driving the growth of the market.

Moreover, there is growing interest in improving the stem cell culture, because this technology is being used extensively in research for studying the stem cell biology, as well as for therapeutic applications. Furthermore, funding related to this research field has augmented in recent years which has accelerated the growth of the market. In addition to this, key media manufacturers launched new products for stem cell research. For instance, in September 2021, Bio-Techne Corporation launched a novel medium for the maintenance and expansion of induced pluripotent stem cells having applications in both translational and research workflows.

The outbreak of COVID-19 pandemic has improved the demand for well-established cell-based vaccine production technologies. Moreover, it has given rise to a few scientific innovations, particularly in the production and testing of vaccine technology. For instance, the Vero line originated from the African green monkey kidney and has been extensively used for viral vaccine manufacturing. It has also been used for the development of various SARS-CoV variants. ProVeroTM1 Serum-free Medium is one such medium manufactured by Lonza Bioscience which is protein-free, and of non-animal origin designed to support the growth of Vero cells and MDCK.

Moreover, in many European countries, cell-based flu vaccines have been approved. A probable advantage of cell culture technology is that it authorizes faster start-up of the manufacturing of vaccines during the pandemic. Today, the development of superior biological models, the optimization of culture growth medium, and the reduced dependence on animal-derived components endure to drive the rapidly developing vaccine development.

On the other hand, ethical issues concerning the use of animal-derived products hinders the industry growth. For instance, FBS is collected from the blood of fetal calves is one of the major ethical issues of serum containing media. It is projected that 600,000 liters of FBS is achieved from up to 1.8 million bovine fetuses are produced globally every year, presenting momentous scientific and ethical challenges. To overcome this issue, numerous workshops were held in the past on the replacement of fetal bovine serum and possible ways to reduce the use of FBS in media.

Cell Culture Media Market Segmentation

Grand View Research has segmented the global cell culture media market based on product, application, type, end-user, and region:

Cell Culture MediaMarket - Product Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Application Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Type Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - End-user Outlook (Revenue, USD Million, 2018 - 2030)

Cell Culture MediaMarket - Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

List of Key Players of Cell Culture Media Market

Check out more related studies published by Grand View Research:

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: +1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected] Web: https://www.grandviewresearch.com Grand View Compass| Astra ESG Solutions Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

SOURCE Grand View Research, Inc.

The rest is here:
Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire

Posted in Stem Cell Research | Comments Off

[Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For ‘The First Time in The World’ – Digital…

Posted: July 27, 2022 at 3:12 am

LOS ANGELES, CA, July 27, 2022 /24-7PressRelease/ A global genome analysis service and AI-based new drug development company , Theragen Bio (CEO, Tae-soon Hwang),announced on the 19th that they recently published a jointly research paper with Gilo Foundation, Yonsei University, University of Tsukuba in Japan, and MedPacto (235980) in the July issue of Nature Communications (IF: 17.694), which is an online sister journal of Nature, a world-renowned academic journal.

The results of thls study, led by Gilo Foundation (hereafter Gilo), where CEO of MedPacto, Sung-jin Kim is also serving as the research director, showed that the MAST4 protein is a key protein that determines the differentiation of Mesenchymal Stem Cell (MSC) into cartilage or bone cells.

The results of thls study are significant that Korean researchers have discovered a new protein (MAST4)for the first in the world that can take crucial role in the treatment of various cartilage and bone loss such as osteoporosis and rheumatoid arthritis, which areintractablebone joint diseasein the aging population.

An official from the research center said, We found that MAST4 protein controls cartilage differentiation, but promotes bone differentiation.It was the first time in the world to prove the fact that without MAST4 protein, MSC will differentiate into cartilage cell, and when MAST4 protein increases, MSC differentiate into bone cell.

The research team also confirmed that the cartilage differentiation and generation of mesenchymal stem cells was promoted when stem cells deficient in MAST4 protein were inoculated and transplanted into mice subcutaneously. Also, in the rabbit cartilage damage treatment model, it was confirmed that when human-derived bone marrow cells deficient in MAST4 protein were transplanted, the damaged cartilage tissue was completely regenerated.

A company official said, MSC has low immunogenicity, which makes it is easy to secure cells because both autologous and homologous cells can be used. After that, we can remove gene from MAST4 protein with gene scissors and transplant MSC to use them for restoration of cartilage, which has high potential of becoming groundbreaking treatment.It will greatly contribute to regenerative medicine in thls field.

Dr. Chang-pyo Hong from Theragen Bio took a big role in proving through transcrlptome data analysis that MAST4 is regulated by TGF- and Wnt signaling in thls joint study.

Dr. Hong said, thls research paper discovered MAST4 protein which is an important central mediator of the previously known TGF- and Wnt signaling, and newly unravels the link between the bone and cartilage differentiation process. It is expected to contribute significantly to the treatment of bone joint diseaseand the development of regenerative medicine in the future.

Nature Communication is a peer-reviewed, open access, SCI-level scientific journal published by Nature Research since 2010. They publish major research results in the natural sciences, including physics, chemistry, earth science, medicine, and biology.

Source: Pangyo Techno Valley Official Newsroom

PANGYO TV

Press release service and press release distribution provided by http://www.24-7pressrelease.com

See the rest here:
[Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For 'The First Time in The World' - Digital...

Posted in Stem Cell Research | Comments Off

Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -…

Posted: July 27, 2022 at 3:12 am

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type, Cryogen Type, Application, and End User" report has been added to ResearchAndMarkets.com's offering.

The cryopreservation equipment market is expected to reach US$ 12,489.84 million by 2028 from US$ 6,358.65 million in 2022; it is estimated to grow at a CAGR of 11.9% from 2022 to 2028.

The factors such as growing acceptance for regenerative medicine and increasing need of biobanking practices are contributing to the market growth. However, the stringent regulatory requirements hinder the cryopreservation equipment market growth.

Cryopreservation is a technique employed to minimize cell damage caused during freezing and storage of biological materials such as tissue, bacteria, fungi, virus, and mammalian cells. Tissues and genetically stable living cells preserved via cryopreservation can be used in research and other biomedical applications. The equipment required for cryopreservation includes cryopreservation systems, cryoware, accessories, and cryogen.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.

Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.

Type Insights

Based on type, the global cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2021, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR in the market during 2022-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

Cryogen Type Insights

Based on cryogen type, the global cryopreservation equipment market is segmented into liquid nitrogen, oxygen, liquid helium, argon, and others. In 2021, the liquid nitrogen segment held the largest share of the market; the market for this segment is further expected to grow at the highest CAGR during 2022-2028. Liquid nitrogen is a nonmechanical method of cells preservation. Large thermos-like containers are used to house either racks or shelves that hold cryogenic vials.

Application Insights

Based on application, the global cryopreservation equipment market is segmented into cord blood stem cells, sperms, semen & testicular tissues, embryos and oocytes, cell and gene therapies, and others. In 2020, the cord blood stem cells segment held the largest share of the market. Moreover, the market for the sperms segment is expected to register the highest CAGR in the market during 2022-2028. In recent years, public cord banking has been promoted over private cord banking. Various centers across the world are performing cord blood stem cell transplantation as a part of the management of genetic, hematologic, immunologic, metabolic, and oncologic disorders, among others, which is bolstering the growth of the market for the public cord banking segment.

End User Insights

Based on end user, the cryopreservation equipment market is segmented into stem cell banks, biotechnology and pharmaceuticals organizations, stem cell research laboratories, and others. The biotechnology and pharmaceuticals organizations segment held the largest market share in 2020, and it is further expected to be the largest shareholder in the market by 2028. Cryopreservation has become an integral part of the manufacturing process of many cellular therapies as it sometimes precedes cell culture (by preserving the starting cellular material before beginning large-scale manufacturing) and generally follows cell expansion.

Key Topics Covered:

1. Introduction

2. Cryopreservation Equipment Market - Key Takeaways

3. Research Methodology

4. Global Cryopreservation Equipment Market - Market Landscape

5. Cryopreservation Equipment Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Acceptance for Regenerative Medicine

5.1.2 Increasing Needs of Biobanking Practices

5.2 Market Restraints

5.2.1 Stringent Regulatory Requirements

5.3 Market Opportunities

5.3.1 Importance of Cryopreservation for Success of Cell-Based Therapies

5.4 Future Trends

5.4.1 3D Printing to Provide Customizable Probes for Sensing and Monitoring in Cryobiology Applications

5.5 Impact Analysis

6. Cryopreservation Equipment Market- Global Analysis

7. Global Cryopreservation Equipment Market Revenue and Forecasts To 2028- by Type

10. Cryopreservation Equipment Market Revenue and Forecasts To 2028 - End User

11. Cryopreservation Equipment Market Revenue and Forecasts to 2028 - Geographical Analysis

12. Impact Of COVID-19 Pandemic on Cryopreservation Equipment Market

13. Cryopreservation Equipment Market- Industry Landscape

14. Company Profiles

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/l7syls

See the rest here:
Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -...

Posted in Stem Cell Research | Comments Off

‘I kept thinking I was having a heart attack but it was the perimenopause’ – iNews

Posted: July 27, 2022 at 3:09 am

Becky Maynard has spent 10 years working in many international humanitarian crises, dealing with everything from earthquakes to refugees, and then did a Masters in Disaster Management. Consequently, you might expect her to be more resilient than most in dealing with the perils of the perimenopause, but like so many women, she was knocked sideways by mystery symptoms.

Her problems began when she was 44, driving home to Cornwall, and pulled her car over three times. I kept thinking I was having a stroke or a heart attack, says Maynard, now 48. I drew into a lay-by, realising there was no way I could drive any further because I was going to die.

She asked a lorry driver parked nearby to help, saying, I dont know whats happening. I cant be alone. He tried some breathing exercises with her and called a friend. Three hours later, she managed to drive herself home.

She wondered if she was suffering from PTSD from her work, was diagnosed with panic attacks and offered cognitive behavioural therapy, which didnt help much. Then she was given antidepressants: [They] made no difference. I continue to have constant anxiety, gain weight and feel utterly miserable. When she began to suspect her problems might be linked to hormones, she asked about hormone replacement therapy [HRT], but her GP told her to come back two years after your periods have stopped.

But Maynard had been on a pill that meant she was not having periods. So she started researching her symptoms and discovered they are common in the years leading up to menopause. Its been a revelation finding out about perimenopause, and Ive decided to see a different GP to discuss HRT, she said.

Perimenopause is menopauses dastardly little sister. On no account should it be underestimated, as it moves by stealth. Women in their forties find themselves flummoxed by a raft of mental and physical symptoms, and blame themselves instead of their changing hormones, because they usually still have their periods.

Until recently, there was silence and ignorance around perimenopause among women and even doctors, and only now is it beginning to get the attention it needs. If you looked on the NHS website three months ago, there was only one vague mention of the word perimenopause, but now (in a slight improvement) the site describes symptoms of perimenopause and menopause as one item.

But the emotional and physical rollercoaster of perimenopause needs far more explanation than that: it is a time of anxiety, sleeplessness and physical change for most. Suicide peaks among women, and divorce rises. In midlife, usually when women are in their mid-to-late forties, oestrogen and progesterone unpredictably drain and refill like rip tides, and then decline along with testosterone, which is also a female hormone. Every day can be different.

It is not merely the onlookers, families and friends that dont realise whats going on. Women themselves (along with some non-binary people and trans men who go through this process) often have no idea. Perimenopause can seriously affect mental health.

I am the producer of two recent Davina McCall menopause documentaries for Channel 4, and it was the perimenopause rather than the menopause that caused havoc in the TV presenters life. McCall was 44 when she started getting hot flushes, anxiety and brain fog that stopped her reading the autocue: I thought I had early onset dementia, she said.

For me, the perimenopause brought peculiar symptoms: terrifying heart palpitations in the early hours and overwhelming anxiety, as well as sudden gaps in my memory bank. The heart palpitations led to an electrocardiogram, which was just fine Im a regular runner. The doctor concluded the cause was too much coffee. Menopause was never mentioned, but the palpitations disappeared and my memory rebooted as soon as I sought out HRT.

I was so astonished at the lack of reliable information that I wrote a book, Everything You Need to Know About the Menopause (but were too afraid to ask) and discovered there were huge gaps in research, particularly around perimenopause. I only found out how common some of my own symptoms were after we commissioned a Channel 4/Fawcett Society poll of 4,000 women aged 45-55 for the second programme, Davina McCall: Sex, Mind and the Menopause. It turned out that 41 per cent had experienced difficulties with heart palpitations, and 73 per cent had brain fog and memory problems.

With menopause coming on average at 51 (though it can be younger, particularly for Black and Asian women) it was important to include women in their late forties in the poll, and what resonated was that 69 per cent suffered anxiety and depression, and 84 per cent sleeplessness. There was one other key finding 44 per cent said they had uncomfortably heavy periods in perimenopause. These flooding, tsunami-style periods stop some women leaving the house, and others need more access to the bathroom at work.

Theres no one-size-fits-all set of symptoms that define perimenopause, say nutritionist Emma Bardwell and menopause specialist Dr Shahzadi Harper in their book, The Perimenopause Solution. Hot flushes are not always the signifier. NHS guidelines say that women under 45 can be given a blood test to see if their hormones are low. But if your blood test comes back normal, you might think you cant possibly be in perimenopause. What you need to know is this: its not about the numbers, its about how you feel.

Bardwell and Harper say: Many GPs are still reluctant to prescribe hormone replacement therapy to women in perimenopause who still have their periods, even when symptoms are signalling hormonal change and a call for help.

As Becky Maynard found, perimenopause is often not identified as a possible cause of mental-health symptoms. That means women may miss out on effective treatment for their anxiety or depression.

Menopausal depression is different from clinical depression, and usually responds to hormones. Patients who have never previously been depressed describe low mood, a grey, flat kind of feeling, a loss of joy, said Dr Rebecca Lewis, a GP turned menopause specialist at the Newson Heath Menopause and Wellbeing Centre in Stratford-Upon-Avon. The reason women come to see me most in the clinic is not the hot flushes, not the muscle pains, but the psychological changes. As eggs begin to run out in perimenopause, that starts fluctuations in hormones which affect the brains limbic system, which governs anxiety, mood, libido and concentration.

So what can women do if they suspect they are perimenopausal? Obviously paying attention to lifestyle choices really matters and Bardwell points out that changing hormones can cause bloating and even alcohol intolerance. A diet overhaul is a good idea, looking after your gut microbiome and making sure you get enough vegetables, vitamin D, fish oils and even magnesium, which can help with sleep.

Exercise has also been shown to reduce hot flushes, but nothing can replace lost hormones except hormones themselves, and the new body-identical HRT available on the NHS is safer than the older preparations. A body-identical progesterone pill and transdermal oestrogen in a patch, gel or spray showed no increased risk of breast cancer in a 2022 study of almost half a million womens records in the UK databank.

One of the best resources, with more detailed information than the NHS website, is the balance-menopause.com website, and the free Balance app. Balances chief executive Gaele Lalahy explains: The app allows users to track their symptoms and print an individualised health report which they can take to their doctor. More than 250,000 health reports have been downloaded, and more than half of women who had been using the app for more than five months said it had helped them to access treatment faster.

We need to empower women with accurate information, and in turn improve their physical and mental health, as well as their quality of life.

Weve had period power. Now we need to talk about the perimenopause power and take control of our hormones.

Everything You Need to Know About the Menopause (but were too afraid to ask) by Kate Muir (Gallery Books, 16.99) is out now

See the rest here:
'I kept thinking I was having a heart attack but it was the perimenopause' - iNews

Posted in Testosterone Replacement Therapy | Comments Off

Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study – NutraIngredients-Asia

Posted: July 27, 2022 at 3:09 am

The study was conducted by Hanyang University, with the findings published in Nutrients recently.

It assessed the relationship between micronutrient intake and breast cancer risk using a standardised semi-quantitative food frequency questionnaire (FFQ).

A total of 103 food items, excluding dietary supplements, were included in the FFQ to assess the womens intake of micronutrients from their diets.

A total of 40,432 women without a history of cancer were included to take part in the survey. These women were selected to take part in the survey based on the Korean Genome and Epidemiology Study (KoGES).

After completing the survey, the researchers followed up on these women for an average of 4.9 years.

By the end of the follow-up, a total of 232 women reported that they had been diagnosed with breast cancer by a physician.

Breast cancer was the most common cancer in women, accounting for 23,647 (20.5%) cases of cancer, according to the 2018 cancer registration statistics in South Korea.

Risk factors include the lifestyle, the level of physical activity, alcohol consumption, as well as the age at which they gave birth, the number of births, breastfeeding experience and duration, and the use of hormone replacement therapy after menopause.

Findings showed that the intake of vitamin C and vitamin B6 above the daily recommended value based on the 2020 Dietary Reference Intakes for Koreans (KDRIs) was associated with a reduced risk in obese women.

However, no significant association was not observed in women with normal weight.

Obesity is associated with higher estrogen levels in postmenopausal women due to the aromatase change of testosterone to estrogen in adipose tissue, as well as chronic inflammation status with increased oxidative stress permanently.

Thus, the antioxidant effect of vitamin C may be more prominent in women with obesity, the researchers explained.

As for the impact seen from vitamin B6, the researchers said this could be because the vitamin was involved in insulin resistance and could control adipogenesis-related genes, or fat-related genes.

A protective association of high vitamin B6 intake was observed only in obese women. Studies have suggested that vitamin B6 is also involved in insulin resistance by controlling the expression of adipogenesis-related genes. Thus, the protective effect may be more prominent in women with obesity.

The research was supported by a National Research Foundation of Korea grant funded by the South Korean government.

Source: Nutrients

Association between Micronutrient Intake and Breast Cancer Risk According to Body Mass Index in South Korean Adult Women: A Cohort Study

https://doi.org/10.3390/nu14132644

Authors: Song, H.; Jeong, A.; Tran, T.X.M.; Lee, J.; Kim, M.; Park, B.

Read the original:
Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study - NutraIngredients-Asia

Posted in Testosterone Replacement Therapy | Comments Off

Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of…

Posted: July 27, 2022 at 3:07 am

See the original post:
Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of...

Posted in Genetic medicine | Comments Off

Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS – PR Newswire

Posted: July 27, 2022 at 3:07 am

CARLSBAD, Calif., July 26, 2022 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tofersen, an investigational antisense medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS). The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a Prescription Drug User Fee Act action date of Jan. 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application. The average life expectancy for people with ALS is three to five years from time of symptom onset; patients with some SOD1 mutations have an even shorter life expectancy. There is currently no treatment targeted for SOD1-ALS.

"Acceptance of the new drug application for tofersen is a monumental milestone, not just for Ionis but for all people with SOD1-ALS, their families and healthcare professionals battling this devastating disease. To them we extend our deepest gratitude. Their courage has been instrumental to the achievement of this goal," said C. Frank Bennett, Ph.D., executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis. "We also want to thank Biogen for their commitment to advancing tofersen, which, if approved, will be the first treatment that targets a genetic cause of ALS." Dr. Bennett added, "Acceptance of the NDA for tofersen further strengthens Ionis' platform strategy to target all forms of ALS and central nervous system disorders more broadly."

Biogen is seeking approval of tofersen under the FDA's accelerated approval pathway, based on the use of neurofilament as a surrogate biomarker that is reasonably likely to predict clinical benefit. Neurofilaments are normal proteins found in healthy neurons, that are increased in blood and cerebrospinal fluid when damage has been done to neurons or their axons and are a marker of neurodegeneration. In ALS, higher levels of neurofilaments have been found to predict more rapid decline in clinical function and shortened survival. Tofersen study results suggest reductions in neurofilament preceded and predicted slowing of decline in measures of clinical and respiratory function, strength and quality of life. Biogen has stated its commitment to ongoing data generation and finalizing the confirmatory package with the FDA.

The tofersen NDA included results from a Phase 1 study in healthy volunteers, a Phase 1/2 study evaluating ascending dose levels, the Phase 3 VALOR study, and the open label extension (OLE) study. Also included are the most current 12-month integrated results from VALOR and the OLE study, recently presented at the European Network to Cure ALS (ENCALS) annual meeting.

As reported in October 2021, VALOR, a six-month Phase 3 randomized study, did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. However, trends of reduced disease progression across multiple secondary and exploratory endpoints were observed. The 12-month VALOR and OLE integrated data showed that earlier initiation of tofersen led to sustained reductions in neurofilament, a marker of neurodegeneration, and slowed decline across multiple efficacy endpoints.

In the 12-month data, the most common adverse events (AEs) in participants receiving tofersen in VALOR and the OLE study were headache, procedural pain, fall, back pain and pain in extremities. Most AEs in both VALOR and the OLE were mild to moderate in severity. Serious AEs were reported in 36.5 percent of participants who received tofersen in VALOR and/or the OLE and 17.3 percent of participants discontinued treatment due to an AE.

During the FDA review period Biogen will maintain its early access program for tofersen, now with participants in over a dozen countries. The open-label extension and Phase 3 ATLAS study in presymptomatic individuals with a SOD1 genetic mutation remain ongoing. Biogen is actively engaging with other regulators around the world and will provide updates when appropriate.

About Tofersen

Tofersen is an antisense medicine being evaluated for the potential treatment of SOD1-ALS. Tofersen binds to SOD1 mRNA, allowing for its degradation by RNase-H in an effort to reduce synthesis of SOD1 protein production. In addition to the ongoing open label extension of VALOR, tofersen is being studied in the Phase 3 ATLAS study designed to evaluate whether tofersen can delay clinical onset when initiated in presymptomatic individuals with a SOD1 genetic mutation and biomarker evidence of disease activity. Biogen licensed tofersen from Ionis under a collaborative development and license agreement.

About Amyotrophic Lateral Sclerosis and SOD1-ALS

Amyotrophic lateral sclerosis (ALS) is a rare, progressive and fatal neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord that are responsible for controlling voluntary muscle movement. People with ALS experience muscle weakness and atrophy, causing them to lose independence as they steadily lose the ability to move, speak, eat, and eventually breathe. Average life expectancy for people with ALS is three to five years from time of symptom onset. Patients with some SOD1 mutations have an even shorter life expectancy.

Multiple genes have been implicated in ALS. Genetic testing helps determine if a person's ALS is associated with a genetic mutation, even in individuals without a family history of the disease. Currently, there are no genetically targeted treatment options for ALS. Mutations in the SOD1 gene are responsible for approximately 2 percent of the estimated 168,000 people who have ALS globally (SOD1-ALS).

AboutIonis Pharmaceuticals, Inc.

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company.

To learn more about Ionis visit http://www.ionispharma.com and follow us on Twitter @ionispharma.

Ionis' Forward-looking Statements

This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of Ionis' technologies, tofersen and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those related to the impact COVID-19 could have on our business, and including but not limited to, those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.

Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2021, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers toIonis Pharmaceuticalsand its subsidiaries.

Ionis Pharmaceuticals is a trademark ofIonis Pharmaceuticals, Inc.

SOURCE Ionis Pharmaceuticals, Inc.

Posted in Genetic medicine | Comments Off

Startup aiming to push boundaries of gene therapy nets $55M in seed cash – MedCity News

Posted: July 27, 2022 at 3:07 am

Genetic medicines have a capacity problem. The engineered viruses used to deliver them have limited room for their genetic cargo, which in turn limits the way diseases can be treatedif they can be treated at all. A new biotech company named Replay has assembled a suite of technologies that could enable it to deliver big genes or even multiple genes, and it has emerged with $55 million to advance its research.

The seed round announced Monday was led by KKR & Co. and OMX Ventures.

The delivery vehicle of choice for many experimental genetic medicines is the adeno-associated virus (AAV), which can be engineered to ferry DNA to target cells. The capacity of AAV is just under 5 kilobases (kb). San Diego-based Replay claims it can achieve a payload capacity up to 30 times greater. It aims to do so with its synHSV technology, which employs an engineered herpes simplex virus (HSV). In addition, Replays toolkit includes technologies that enable it to efficiently write its big genes and big DNA, and a technology that can produce off-the-shelf therapies.

The capacity limitation of AAV is apparent in the research of genetic medicines for Duchenne muscular dystrophy. Sarepta Therapeutics, Solid Biosciences and Pfizer have reached clinical testing with their respective gene therapies, each one engineered to deliver a functioning version of the gene needed to treat the inherited muscle-wasting disorder. But the genes that produce the key protein at the root of Duchenne are big, so the therapies are comprised of micro versions of the gene small enough to fit on an AAV vector.

Duchenne is one of the disease targets of Replay. The therapy in development for that muscle-weakening disorder is 14 kb, according to the companys website. But Replay wont be going directly head to head against the field of potential gene therapies for Duchenne. Under Replays business model, the various technologies it owns are developed in a disease-agnostic way. When Replay identifies an area that can specifically be addressed by one or more of its technologies, it forms a product company to pursue that area. The Duchenne research is housed in one such product company.

Technology and product development have different talent requirements, timelines, costs and cultures, Replay CEO and co-founder Lachlan MacKinnon said in a prepared statement. By separating technology development from product development, we have generated a model to accommodate these differences. Our ability to write and deliver big DNA has the potential to disrupt many areas of genomic medicine.

Replay says it has formed five product companies to date. In the eye, one company is focused on retinitis pigmentosa, a group of rare retinal disorders that leads to degeneration of photoreceptors. The Replay website lists two gene therapy constructs for retinitis pigmentosa: one is 7 kb and the other is 9 kb. A Replay skin product company is developing a treatment for dystrophic epidermolysis bullosa, an inherited disorder that leads to extremely fragile skin that is prone to widespread blistering. The experimental therapy of that company is 19.2 kb. Replays brain product company has the biggest of its genetic medicines in development, a 40 kb therapy for Parkinsons disease. A fifth product company is focused on enzyme writing.

There are other startups that, like Replay, are turning to AAV alternatives in the quest for better genetic medicines. Last month, Philadelphia-area startup Code Bio closed a $75 million Series A round of funding to support the development of synthetic DNA-based therapies for two lead indications, Duchenne and type 1 diabetes.

The new round of financing for Replay included participation from Artis Ventures, Lansdowne Partners, SALT, DeciBio Ventures and Axial.

Photo: iLexx, Getty Images

Read the original here:
Startup aiming to push boundaries of gene therapy nets $55M in seed cash - MedCity News

Posted in Genetic medicine | Comments Off

Monthly Archives: July 2022

STEMTECH CORPORATION Partners with VERB in Launching Interactive Video and Livestreaming Sales Enablement Apps to Strengthen Direct Sales Channel -…

Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell…

Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. – PR Newswire

[Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For ‘The First Time in The World’ – Digital…

Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -…

‘I kept thinking I was having a heart attack but it was the perimenopause’ – iNews

Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study – NutraIngredients-Asia

Ethical Considerations in Precision Medicine and Genetic Testing in Internal Medicine Practice: A Position Paper From the American College of…

Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS – PR Newswire

Startup aiming to push boundaries of gene therapy nets $55M in seed cash – MedCity News

Categories

Archives

Recommended Sites

Contact Us

Recent Posts